Equillium Announces Three Abstracts Accepted for Presentation at the 104th AAI Annual Meeting
- emailcarey
- Apr 27, 2021
- 1 min read
Updated: May 12, 2021
Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients
Comments